Format

Send to

Choose Destination
3 Biotech. 2018 Aug;8(8):341. doi: 10.1007/s13205-018-1369-x. Epub 2018 Jul 27.

Production of biologically active feline interferon beta in insect larvae using a recombinant baculovirus.

Author information

1
1Facultad de Farmacia y Bioquímica, Cátedra de Biotecnología, Universidad de Buenos Aires, Junín 956, 1113 Buenos Aires, Argentina.
2
2Instituto de Nanobiotecnología (NANOBIOTEC), CONICET-Universidad de Buenos Aires, Junín 956, 1113 Buenos Aires, Argentina.
3
3Unidad de Transferencia Genética, Instituto de Oncología "Ángel H. Roffo", Universidad de Buenos Aires, Av. San Martín 5481, 1417 Buenos Aires, Argentina.
4
4Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.

Abstract

Feline interferon beta is a cytokine that belongs to the type I IFN family, with antitumor, antiviral and immunomodulatory functions. In this work, recombinant feline interferon beta (rFeIFNβ) was expressed in insect larvae that constitute important agronomic plagues. rFeIFNβ accumulated in the hemolymph of Spodoptera frugiperda larvae infected with recombinant baculovirus and was purified by Blue-Sepharose chromatography directly from larval homogenates on day 4 post-infection. rFeIFNβ was recovered after purification with a specific activity of 1 × 106 IU mg-1. By this method, we obtained 8.9 × 104 IU of purified rFeIFNβ per larva. The product was biologically active in vitro, with an antiviral activity of 9.5 × 104 IU mL-1, as well as a potent antitumor activity comparable to that of the commercial FeIFNω. The glycosylation of rFeIFNβ was confirmed by peptide-N-glycosidase F digestion. Our findings provide a cost-effective platform for large-scale rFeIFNβ production in laboratory research or veterinary medicine applications.

KEYWORDS:

Baculovirus; Feline interferon beta; Insect larvae; Veterinary medicine

PMID:
30073126
PMCID:
PMC6063813
[Available on 2019-08-01]
DOI:
10.1007/s13205-018-1369-x

Conflict of interest statement

Compliance with ethical standardsThe authors declare that they have no conflict of interest in the publication.

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center